Enveda
Founded Year
2019Stage
Series D | AliveTotal Raised
$535.5MValuation
$0000Last Raised
$150M | 2 mos agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+75 points in the past 30 days
About Enveda
Enveda operates as a biotechnology company using artificial intelligence (AI) to assist in the development of medicines. The company identifies and characterizes a variety of molecules produced by living organisms, some of which have not been scientifically explored, creating a database of chemical biodiversity. The database is used by Enveda to address medical challenges. Enveda was formerly known as Enveda Therapeutics. It was founded in 2019 and is based in Boulder, Colorado.
Loading...
Loading...
Research containing Enveda
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Enveda in 4 CB Insights research briefs, most recently on Oct 28, 2025.
Oct 28, 2025 report
State of Digital Health Q3’25 Report
Sep 19, 2025 report
Book of Scouting Reports: AI Drug Discovery
May 23, 2025
The AI in drug R&D market map
Expert Collections containing Enveda
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Enveda is included in 5 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,297 items
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Artificial Intelligence (AI)
20,629 items
AI in drug discovery
528 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
Latest Enveda News
Nov 2, 2025
Sediul central: Colorado, SUA Total finanţări: aproximativ 530 de milioane de dolari Evaluare curentă: 1,2 miliarde de dolari după finanţarea de 150 de milioane de dolari din septembrie 2025 Model de business: dezvoltă o platformă care integrează AI şi automatizare pentru a identifica molecule naturale cu potenţial terapeutic care au fost neexplorate de industria farmaceutică. Prin această platformă, compania îşi generează singură pipeline-ul de candidaţi (descoperire, dezvoltare preclinică, clinic) şi valorifică potenţialele medicamente, colaborând cu investitori şi companii farmaceutice. Cifre cheie: peste 16 programe preclinice; aproximativ 312 angajaţi. Povestea pe larg Enveda a fost fondată în 2019 de Viswa Colluru (fost angajat la Recursion Pharmaceuticals) cu obiectivul de a folosi inteligenţa artificială pentru a descoperi noi medicamente, scrie CTOL Digital Solutions. În 2020, într-o rundă de tip seed, compania a ridicat o finanţare de aproximativ 4,9 mil. de dolari pentru a construi o bază de date cu plante medicinale şi compuşi naturali, potrivit Crunchbase News. În iunie 2021, Enveda a ridicat o finanţare Seria A în valoare de 51 milioane de dolari, scrie FinSMEs. Iar în decembrie 2022, compania a anunţat o rundă serie B în valoare de 68 mil. de dolari, conform BioSpace. În iunie 2024, compania a mai atras o finanţare, în valoare de 55 milioane de dolari, pentru avansarea programelor preclinice, mai scrie CTOL Digital Solutions. În noiembrie 2024, Enveda a anunţat că a ridicat o investiţie de 130 mil. de dolari, potrivit informaţiilor publicate pe site-ul companiei. În septembrie 2025, compania a anunţat o rundă de finanţare în valoare de 150 de milioane de dolari care a urcat evaluarea Enveda la 1,2 miliarde de dolari, atingând astfel statutul de unicorn, potrivit Pitchbook şi Fiercebiotech. Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels Citește și
Enveda Frequently Asked Questions (FAQ)
When was Enveda founded?
Enveda was founded in 2019.
Where is Enveda's headquarters?
Enveda's headquarters is located at 5700 Flatiron Parkway, Boulder.
What is Enveda's latest funding round?
Enveda's latest funding round is Series D.
How much did Enveda raise?
Enveda raised a total of $535.5M.
Who are the investors of Enveda?
Investors of Enveda include FPV Ventures, Lux Capital, Kinnevik, Level Ventures, Lingotto and 31 more.
Who are Enveda's competitors?
Competitors of Enveda include Brightseed and 5 more.
Loading...
Compare Enveda to Competitors
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions, and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
BioSymetrics integrates clinical and experimental data with machine learning to develop precision medicines. The company focuses on target discovery and precision medicine development, using clinical data and in vivo validation to find new drug targets. BioSymetrics serves sectors involved in neurological, cardiometabolic, and rare disease research and drug development. It was founded in 2015 and is based in Huntington, New York. In February 2025, BioSymetrics was acquired by Renovaro BioSciences.
Nuritas engages in the discovery and development of bioactive peptides for various industries using artificial intelligence. Its offerings include peptide-based ingredients for dietary supplements, functional foods and beverages, medical foods, and cosmetics. The company serves the food and beverage, health and wellness, and cosmetics sectors with peptide solutions. It was founded in 2014 and is based in Dublin 2, Ireland.
Gandeeva Therapeutics is a medicine company that engages in drug discovery within the biotechnology sector. The company utilizes artificial intelligence and cryogenic electron microscopy to develop therapies that target protein interactions, particularly in oncology. Gandeeva Therapeutics collaborates and licenses technologies and has a team in structural biology, computer science, and medicinal chemistry. It was founded in 2021 and is based in Burnaby, Canada.
Pathos is a clinical-stage biotechnology focuses on the re-engineering of drug development using AI technologies. It provides services such as optimizing patient selection strategies and developing precision medicines. Pathos serves the biopharmaceutical industry by partnering to advance clinical-stage therapeutics. It was founded in 2022 and is based in Chicago, Illinois.
Metanovas focuses on health and beauty within the cosmetics, medical aesthetics, and functional foods sectors. The company specializes in developing nutraceutical and cosmeceutical products utilizing artificial intelligence and biotechnology to create products that enhance overall well-being. Metanovas collaborates with global brands to offer solutions in these areas. It was founded in 2021 and is based in Foster City, California.
Loading...